Use of CD40L immunoconjugates to overcome the defective immune response to vaccines for infections and cancer in the aged

Cancer Immunology, Immunotherapy

Volumn 58, Issue 12, 2009, Pages 1949-1957

  Tang, Yu Cheng ^a   Thoman, Marilyn ^a   Linton, Phyllis Jean ^a   Deisseroth, Albert ^a,b  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

CD40L; Immunoconjugates; MUC 1; Vaccines

Indexed keywords

ANTIBODY CONJUGATE; CANCER VACCINE; CD40 LIGAND; VACCINE;

AGING; ANIMAL; HUMAN; IMMUNOLOGY; INFECTION; MOUSE; NEOPLASM; REVIEW;

AGING; ANIMALS; CANCER VACCINES; CD40 LIGAND; HUMANS; IMMUNOCONJUGATES; INFECTION; MICE; NEOPLASMS; VACCINES;

EID: 79958172278     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0718-3     Document Type: Conference Paper

References (39)

1. Castle SC (2000) Clinical relevance of age-related immune dysfunction. Clin Infect Dis 31:578
2. Ortqvist A, Granath F, Askling J, Hedlund J (2007) Influenza vaccination and mortality: prospective cohort study of the elderly in a large geographical area. Eur Respir J 30:414-422 (Pubitemid 351182062)
3. Saurwein-Teissl M, Lung TL, Marx F, Gschosser C, Asch E, Lasko I, Parson W, Bock G, Schnoitzer D, Trannoy E et al (2002) Lack of antibody production following immunization in old age: association with CD8+ CD28- T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol 168:5893
4. Haynes L, Eaton SM, Burns EM, Randall TD, Swain SL (2003) CD4 T cell memory derived from young naïve cells functions well into old age, but memory generated from aged naïve cells functions poorly. Proc Natl Acad Sci USA 100:15053-15058 (Pubitemid 37518015)
5. Jefferson T et al (2005) Efficacy and effect of influenza vaccines in the elderly. Lancet 264:1165-1174
6. Goodwin K, Vibou C, Simonsen L (2006) Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24:1159-1169 (Pubitemid 43202262)
7. Jackson ML, Nelson JC, Weiss NS, Neuzil KM, Barlow W, Jackson LA (2008) Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. The Lancet 372:398-405
8. Simonsen L, Taylor RJ (2007) Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 7:658-666 (Pubitemid 47444564)
9. Eaton SM, Burns EM, Kusser K, Randall TD, Haynes L (2004) Age-related defects in CD4 T cells cognate helper function lead to reductions in humoral responses. J Exp Med 200:1613-1622 (Pubitemid 40094185)
10. Dong L, Mori I, Hossain J, Liu B, Kimura Y (2003) An immunostimulatory oligodeoxynucleotide containing a cytidine-guanosine motif protects senescence-accelerated mice from lethal influenza virus by augmenting the T helper type 1 response. J Gen Virol 84:1623-1628 (Pubitemid 36675534)
11. Deng Y, Jing Y, Campbell AE, Gravenstein S (2004) Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J Immunol 172:3437-3446 (Pubitemid 38337923)
12. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G (1996) Ligation of CD40 on DCs triggers production of high levels of IL-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184:747-752 (Pubitemid 26324129)
13. Prelog M (2006) Aging of the immune system: a risk factor for autoimmunity? Autoimmun Rev 5:136-139
14. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, Ewen C, Kane KP, Bleackley RC (2006) T cell responses are better correlates of vaccine protection in the elderly. J Immunol 176:6333-6339
15. Ishii W, Matsuda M, Hanyuda M, Momose M, Nakayama J, Ehara T, Ikeda S (2007) Comparison of the histological and immunohistochemical features of the thymus in young and elderly onset myasthenia gravis without thymoma. J Clin Neurosci 14:110-115 (Pubitemid 44855614)
16. Shirai T, Yoshiki T, Mellors RC (1972) Age-decrease of cells sensitive to an autoantibody-specific for thymocytes and thymusdependent lymphocytes in NZB mice. Clin Exp Immunol 12:455-464
17. Adkins B, Riley RL (1998) Autoantibodies to T-lineage cells in aged mice. Mech Ageing Dev 103:147-164 (Pubitemid 28356622)
18. Ben-Yehuda A, Weksler ME (1992) Immune senescence: mechanisms and clinical implications. Cancer Invest 10:525-531
19. Singh J, Garber E, Van Vlijmen H, Karpusas M, Hsu YM, Zheng Z, Maismith JH, Thomas D (1998) The role of polar interactions in the molecular recognition of CD40L with its receptor CD40. Protein Sci 7:1124-1135
20. Grewal LS, Flavell RA (1997) The CD40L: at the center of the immune universe? Immunol Res 16:59-70
21. Kornbluth RS (2002) An expanding role for CD40L and other tumor necrosis factor superfamily ligands in HIV infection. J Hematother Stem Cell Res 11:787-801
22. Garcia de Vinuesa C, MacLennan IC, Holman M, Klaus GG (1999) Anti-CD40 antibody enhances responses to polysaccharide without mimicking T cell help. Eur J Immunol 29:3216-3224 (Pubitemid 29484212)
23. Tahara M, Pergolizzi RG, Kobayashi H, Krause A, Luettich K, Lesser ML, Crystal RG (2004) Trans-splicing repair of CD40L deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency. Nat Med 10:835-841 (Pubitemid 39070857)
24. Wierda WG, Cantwell JM, Woods SJ, Rassenti LZ, Preussak CE, Kipps TJ (2000) CD40-ligand (CD154) gene therapy for CLL. Blood 96:2917-2924
25. Vanderheide RH, Dutcher JP, Anderson JE, Eckhardt SG, Stephans KF, Razvillas B, Garl S, Butine MD, Perry VP, Armitage RJ, Ghalie R, Caron DA, Gribben JG (2001) Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 19:3280-3287 (Pubitemid 32591446)
26. Xiang R, Primus FJ, Ruchlmann JM, Niethammer AG, Silletti S, Lode HN, Dolman CS, Gillies SD, Reisfeld RA (2001) Dual function DNA vaccine encoding carcinoembryonic antigen and CD40L trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice. J Immunol 167:4560-4566
27. Karpus M, Hsu YM, Wang JH, Thompson J, Lederman S, Chess L, Thomas D (1995) A crystal structure for an extracellular fragment of human CD40 ligand. Structure 3:1031-1039
28. Zhang L, Tang Y, Linton PJ, Deisseroth A (2003) Injection of Ad vector encoding secretable form of TAA/CD40L fusion protein induces T cell dependent immune response against tumor cells. Proc Natl Acad Sci USA 100:15101-15106
29. Tang Y, Zhang L, Yuan J, Maynard J, Deisseroth A (2004) Vector mediated activation and tumor antigen loading of APC by CD40 ligand/tumor antigen secretory protein generates protection from cancer cell lines. Blood 104:2704-2713
30. Tang Y, Akbulut H, Maynard J, Petersen L, Xiangming Fang, Zhang WW, Xia XQ, Koziol J, Linton PJ, Deisseroth A (2006) Vector prim/protein boost vaccine which overcomes defects acquired during aging and cancer. J Immunol 177:5697-5707 (Pubitemid 44527646)
31. Akbulut H, Tang YC, Akbulut KG, Maynard J, Zhang L, Deisseroth A (2006) Antitumor immune response induced by i.t. injection of vector activated dendritic cells and chemotherapy suppresses metastatic breast cancer. Mol Cancer Ther 5:1975-1985 (Pubitemid 44336569)
32. Akbulut H, Akbulut KG, Tang YC, Maynard J, Deisseroth A (2008) Chemotherapy targeted to cancer tissue potentiates antigen specific immune response induced by vaccine for in vivo antigen loading and activation of dendritic cells. Mol Ther 10:1753-1760
33. Wei XL, Xu H, Kufe D (2004) Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress responses. Cancer Cell 7:167-178 (Pubitemid 40248342)
34. Ahman R, Raina D, Trivedi V, Ren J, Rajabi H, Kharbanda S, Kufe D (2007) MUC1 oncoprotein activates the IkB kinase beta complex and constitutive NF-kB signaling. Nat Cell Biol 9:1419-1435
35. Engelmann K, Shen HM, Finn OJ (2008) CDF7 side population cells with characteristics of stem/progenitor cells express the tumor antigen MUC-1. Cancer Res 68:2419-2426 (Pubitemid 351521817)
36. Treanor JJ, Campbell JD, Zhangwill KM, Rowe T, Wolff M (2006) Safety and immunogenicxity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 254:1343-1351
37. Stephensen I, Nicholson KG, Colegate A, Podda A, Wood J, Ypma E, Zamon M (2003) Boosting immunity to influenza H5N1 with MF 59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 21:1687-1693 (Pubitemid 36287599)
38. Treanor JJ, Schiff GM, Couch RB, Cate TR, Brady RC, Hay M, Wolff M, She D, Cox MMJ (2006) Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis 193:1223-1228
39. Lin JT, Zhang JS, Dong XP, Fang HH, Chen JT, Su N, Gao Q, Zhang ZS, Liu YX, Wang ZH, Yang M, Sun RG, Li CGH, Lin S, Ji M, Liu Y, Want X, Wood HJ, Geng ZJ, Wang Y, Yin WD (2006) Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomized controlled trial. Lancet 368:9912-9997